Genfit (OTCMKTS:GNFTF – Get Free Report) will likely be announcing its resultson Tuesday, September 29th. Analysts expect the company to post earnings of ($0.1827) per share and revenue of $34.8330 million for the quarter.
Genfit Price Performance
Shares of OTCMKTS GNFTF opened at $15.75 on Monday. The stock’s 50-day simple moving average is $15.77 and its 200-day simple moving average is $12.24. Genfit has a fifty-two week low of $4.14 and a fifty-two week high of $16.50.
Genfit Company Profile
Genfit SA is a France-based biopharmaceutical company focused on developing medicines and diagnostic solutions for metabolic, liver and rare diseases. The company’s research programs target conditions with significant unmet medical needs, including metabolic dysfunction-associated steatohepatitis (MASH), primary biliary cholangitis and other progressive liver disorders.
Genfit’s pipeline has included investigational therapies designed to address liver inflammation, fibrosis and related metabolic complications.
Read More
- Five stocks we like better than Genfit
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
